Treatment of malaria in a mouse model by intranasal drug administration

International Journal for Parasitology

Volumn 36, Issue 14, 2006, Pages 1493-1498

  Touitou, Elka ^a   Waknine, Judith H ^a   Godin, Biana ^a   Golenser, Jacob ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Dihydroartemisinin; Drug delivery; Intranasal administration; Malaria; Plasmodium infection

Indexed keywords

DIHYDROARTEMISININ; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID;

DISEASE TREATMENT; DRUG; MALARIA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SMEAR; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; MALARIA; MOUSE; NONHUMAN; PARASITEMIA; PLASMODIUM BERGHEI; SURVIVAL RATE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIMALARIALS; ARTEMISININS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; MALARIA; MALARIA, CEREBRAL; MICE; MICE, INBRED ICR; PARASITEMIA; PLASMODIUM BERGHEI; SESQUITERPENES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

PLASMODIUM BERGHEI; RODENTIA;

EID: 33750967374     PISSN: 00207519     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpara.2006.07.006     Document Type: Article

References (25)

1. Aghazadeh-Habashi A., Sattari S., Pasutto F., and Jamali F. Single dose pharmacokinetics and bioavailability of glucosamine in the rat. J. Pharm. Pharm. Sci. 5 (2002) 181-184
2. Amos S., Chindo B.A., Abbah J., Vongtau H.O., Edmond I., Binda L., Akah P.A., Wambebe C., and Gamaniel K.S. Postsynaptic dopamine (D(2))-mediated behavioural effects of high acute doses of artemisinin in rodents. Brain Res. Bull. 62 (2003) 255-260
3. Ancelin M.L., Calas M., Bonhoure A., Herbute S., and Vial H.J. In vivo antimalarial activities of mono- and bis quaternary ammonium salts interfering with Plasmodium phospholipid metabolism. Antimicrob. Agents Chemother. 47 (2003) 2598-2605
4. Golenser J., McQuillan J., Hee L., Mitchell A.J., and Hunt N.H. Conventional and experimental treatment of cerebral malaria. Int. J. Parasitol. 36 (2006) 583-593
5. Graff C.L., and Pollack G.M. Nasal drug administration: potential for targeted central nervous system delivery. J. Pharm. Sci. 94 (2005) 1187-1195
6. Hermsen C.C., Mommers E., van de Wiel T., Sauerwein R.W., and Eling W.M. Convulsions due to increased permeability of the blood-brain barrier in experimental cerebral malaria can be prevented by splenectomy or anti-T cell treatment. J. Infect. Dis. 178 (1998) 1225-1227
7. Hoshen M.B., Na-Bangchang K., Stein W.D., and Ginsburg H. Mathematical modeling of the chemotherapy of Plasmodium falciparum malaria with artesunate: postulation of 'dormancy', a partial cytostatic effect of the drug, and its implication for treatment regimens. Parasitology 121 (2000) 237-246
8. Karunajeewa H.A., Kemiki A., Alpers M.P., Lorry K., Batty K.T., Ilett K.F., and Davis T.M. Safety and therapeutic efficacy of artesunate suppositories for treatment of malaria in children in Papua New Guinea. Pediatr. Infect. Dis. J. 22 (2003) 251-256
9. Lin A.J., Ager Jr. A.L., and Klayman D.L. Antimalarial activity of dihydroartemisinin derivatives by transdermal application. Am. J. Trop. Med. Hyg. 50 (1994) 777-783
10. Medana I.M., and Turner G.D.H. Human cerebral malaria and the blood-brain barrier. Int. J. Parasitol. 36 (2006) 555-568
11. Mturi N., Musumba C.O., Wamola B.M., Ogutu B.R., and Newton C.R. Cerebral malaria: optimising management. CNS Drugs. 17 (2003) 153-165
12. Nicolas O., Margout D., Taudon N., Wein S., Calas M., Vial H.J., and Bressolle F.M. Pharmacological properties of a new antimalarial bisthiazolium salt, T3, and a corresponding prodrug, TE3. Antimicrob. Agents Chemother. 49 (2005) 3631-3639
13. Omari A.A., Gamble C., and Garner P. Artemether-lumefantrine for uncomplicated malaria: a systematic review. Trop. Med. Int. Health 9 (2004) 192-199
14. O'Neill P.M. The therapeutic potential of semi-synthetic artemisinin and synthetic endoperoxide antimalarial agents. Expert Opin. Investig. Drugs 14 (2005) 117-128
15. Petersen E. Malaria chemoprophylaxis: when should we use it and what are the options?. Expert Rev. Anti-Infect. Ther. 2 (2004) 119-132
16. Peters W., Fleck S.L., Robinson B.L., Stewart L.B., and Jefford C.W. The chemotherapy of rodent malaria. LX. The importance of formulation in evaluating the blood schizontocidal activity of some endoperoxide antimalarials. Ann. Trop. Med. Parasit. 96 (2002) 559-573
17. Touitou E., Dayan N., Bergelson L., Godin B., and Eliaz M. Ethosomes - novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J. Control. Release 65 (2000) 403-418
18. Touitou E., Godin B., Dayan N., Piliponsky A., Levi-Schaffer F., and Weiss C. Intracellular delivery mediated by an ethosomal carrier. Biomaterials 22 (2001) 3053-3059
19. Türker S., Onur E., and Özur Y. Nasal route and drug delivery systems. Pharm. World Sci. 26 (2004) 137-142
20. van Agtmael M.A., Eggelte T.A., and van Boxtel C.J. Artemisinin drugs in the treatment of malaria: from medicinal herb to registered medicine. Trends Pharmacol. Sci. 20 (1999) 199-205
21. White N.J., and Olliaro P. Artemisinin and derivatives in the treatment of uncomplicated malaria. Med. Trop. 58 (1998) 54-56
22. WHO, 2000. Severe falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 94, 1-90.
23. WHO, 2005. World Malaria Report. Available from: .
24. Woodrow C.J., Haynes R.K., and Krishna S. Artemisinins. Postgrad. Med. J. 81 (2005) 71-78
25. Rest J.R. Cerebral malaria in inbred mice. I. A new model and its pathology. Trans. R. Soc. Trop. Med. Hyg. 76 (1982) 410-415